Background: Growth retardation is a common finding in cystic fibrosis (CF) patients. Recombinant human GH (rhGH) has shown promising results in improving weight, height and clinical status of CF patients.
Objective and hypotheses: In this study we aim to evaluate efficacy of rhGH on growth and clinical status in CF patients.
Method: In this prospective clinical trial we recruited 34 CF patients (58.8% male with mean age of 62.05±31.11 months). Patients were followed for 6 months without treatment and then were treated with rhGH 0.35 mg/kg per week for the next 6 months. Measurements included height, weight, growth velocity, pulmonary function, hospitalizations, and outpatient antibiotic use.
Results: Growth velocity, IGF1 levels, hospitalization, and antibiotic therapy were significantly improved after rhGH treatment. 18 patients underwent pulmonary function evaluations including forced vital capacity and forced expiratory volume in 1 min which showed no significant difference with baseline findings.
Conclusion: In conclusion, these results show significant effects of rhGH treatment on growth and clinical status of CF patients.
20 - 22 Sep 2014
European Society for Paediatric Endocrinology